BrightEdge Fund

BrightEdge Fund operates as the American Cancer Society's (ACS) philanthropic impact venture fund, strategically investing in for-profit companies dedicated to developing groundbreaking solutions in the fight against cancer. Established in 2019, BrightEdge's core mission is to accelerate innovation across the cancer care continuum, encompassing diagnostics, therapeutics, digital health, and supportive care. The fund leverages the extensive scientific expertise, vast network, and deep patient insights of the American Cancer Society, offering portfolio companies not just capital but also invaluable strategic guidance and access to a unique ecosystem. This distinctive model allows BrightEdge to bridge the gap between philanthropic efforts and market-driven innovation, aiming to bring life-saving technologies to patients faster.

Since its inception, BrightEdge has demonstrated significant commitment to its mission, having invested over $50 million across more than 20 companies as of early 2024. These investments span various stages, from seed to Series B, reflecting a flexible approach to supporting promising ventures. The fund's initial check sizes typically range from $500,000 to $2 million, indicating a focus on early-stage growth and development. This targeted funding helps nascent companies advance their research, conduct clinical trials, and scale their operations, ultimately contributing to a robust pipeline of cancer-fighting innovations.

The success of BrightEdge's investment strategy is further underscored by the substantial follow-on capital attracted by its portfolio companies. Collectively, these companies have gone on to raise over $1.2 billion in subsequent funding rounds from other venture capital firms and investors. This impressive figure not only validates BrightEdge's selection process but also amplifies the overall impact of its initial investments, demonstrating a strong multiplier effect on philanthropic dollars. By fostering a vibrant ecosystem of cancer innovation, BrightEdge Fund plays a critical role in advancing the American Cancer Society's overarching goal of eradicating cancer and improving the lives of those affected by the disease.